Europeiska unionen - estniska - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Europeiska unionen - estniska - EMA (European Medicines Agency)

idorsia pharmaceuticals deutschland gmbh - daridorexant hydrochloride - unehäirete ja hoolduse häired - psühhoeptikumid - quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.

Europeiska unionen - estniska - EMA (European Medicines Agency)

merck europe b.v. - tepotinib hydrochloride monohydrate - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

Europeiska unionen - estniska - EMA (European Medicines Agency)

novartis europharm limited - asciminib hydrochloride - leukeemia, müelogeenne, krooniline, bcr-abl positiivne - antineoplastilised ained - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.

Europeiska unionen - estniska - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - mitu müeloomit - antineoplastilised ained - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Estland - estniska - Ravimiamet

accord healthcare b.v. - beetahistiin - tablett - 24mg 90tk; 24mg 20tk; 24mg 60tk; 24mg 84tk; 24mg 50tk; 24mg 100tk

Estland - estniska - Ecolab

ecolab deutschland gmbh -

Europeiska unionen - estniska - EMA (European Medicines Agency)

laboratoires delbert - histamiini dihüdrokloriid - leukeemia, müeloidne, äge - immunostimulants, - ceplene maintenance therapy is indicated for adult patients with acute myeloid leukaemia in first remission concomitantly treated with interleukin-2 (il-2). ceplene efektiivsus ei ole täielikult tõestatud üle 60-aastastel patsientidel.

Europeiska unionen - estniska - EMA (European Medicines Agency)

univar solutions bv - trientine dihüdrokloriid - hepatolentikulaarne degeneratsioon - muud alimentary seedetrakti ja ainevahetust tooted, - cufence on näidustatud ravi wilsoni tõbi patsientidel talu, d-penitsillamiin ravi, täiskasvanud ja lapsed vanuses 5 aastat ja vanemad.

Estland - estniska - Ravimiamet

kalceks as - hüdromorfoon - süste-/infusioonilahus - 10mg 1ml 10ml 5tk; 10mg 1ml 1ml 10tk; 10mg 1ml 1ml 5tk; 10mg 1ml 10ml 10tk